Badbir Bstop
BADBIR (the British Association of Dermatologists Biologic and Immunomodulators Register) is a long‑term, prospective pharmacovigilance registry established to monitor the safety and effectiveness of systemic therapies—including biologic agents—in patients with moderate‑to‑severe psoriasis in the United Kingdom and Republic of Ireland. BSTOP (Biomarkers and Stratification To Optimise outcomes in Psoriasis) is a complementary longitudinal observational study that aims to identify biological markers (biomarkers) predictive of treatment response and disease progression by linking clinical data and biological samples, often in conjunction with BADBIR datasets.Overview
Founded Year: BADBIR 2006; BSTOP 2011
Founder: British Association of Dermatologists (BAD) established BADBIR; BSTOP was initiated by Professor Catherine Smith (St John’s Institute of Dermatology) with collaborations across UK dermatology research centres
Purpose: To gather real‑world, long‑term clinical and safety data on psoriasis patients receiving systemic and biologic therapies (BADBIR), and to enable personalised medicine through biomarker identification and stratification of treatment outcomes (BSTOP).
Governing Body
Organisation Name: British Association of Dermatologists; BADBIR Steering Committee; BSTOP Study Group
Company Status: Research collaborative / clinical register and observational study
Regulatory Status: UK ethics‑approved research register and observational cohort functioning under research governance frameworks
Industry Standing: One of the leading clinical pharmacovigilance and biomarker research programmes in dermatology, integrated with academic research bodies and national dermatology centres
Eligibility Criteria
Who Can Apply:
- Patients diagnosed with moderatetosevere psoriasis treated in participating dermatology centres (for BADBIR)
- Subset of these or similar cohorts consenting to additional sample collection for BSTOP
Requirements:
Confirmed diagnosis of moderate‑to‑severe psoriasi...Initiation or modification of systemic or biologic...Informed consent for long‑term data collection and...
Restrictions:
Participation is voluntary and requires clinician ...Contributes data only from participating UK and Re...
Judging Criteria
Evaluation Factors:
Systematic collection of clinical, treatment, laboratory, and outcome metrics (BADBIR)Biological sample quality and research value for biomarker identification (BSTOP)Contribution to peer‑reviewed research outputs and scientific quality
Categories
Available Categories:
Pharmacovigilance register (BADBIR)Biomarker research cohort (BSTOP)
Accreditation Requirements
Inspection Required: Research governance and ethics approvals required for participation and data handling
Documentation Required:
Clinical data forms and follow‑up recordsConsent documentation for patient enrolment and sa...
Compliance Standards:
Adherence to Good Clinical Practice (GCP) and data...Ethics committee approvals for each participating ...
Sources:
Verification Process
Public Register:
- Not a public accreditation register
- Data usage is managed through academic governance and approved research access procedures
Certificate Validation Method: Researchers must submit proposals and secure approval from study governance committees to access BADBIR/BSTOP datasets
Sources:
Renewal & Compliance
Renewal Frequency:
CPD Requirements:
Audit Process: Ongoing research oversight, ethical reviews and data monitoring on longitudinal study conduct
Sources:
Benefits
Reputation: BADBIR is widely recognised as one of the largest and most influential psoriasis treatment registers worldwide, and BSTOP contributes cutting‑edge biomarker research that advances personalised dermatologic medicine.
Patient Trust Impact: Participation supports evidence generation on safety and effectiveness of systemic treatments for psoriasis, improving clinician confidence and patient care pathways.
Patient Safety Impact
Mechanisms of Protection:
Systematic monitoring of adverse events and treatment safety across real‑world patient cohorts (BADBIR)Biomarker research potentially enabling better prediction of therapy response and reduced risk of ineffective or harmful treatment
Limitations:
Not a formal clinical certification; data collection requires patient consent and may not capture all treated individualsDoes not itself provide clinical advice; outputs support academic and clinical guideline development
Comparison with Other Bodies
Comparable Entities:
PSOLAR (Psoriasis Longitudinal Assessment and Registry, USA)PSONET (European psoriasis biologics registry network)
Key Differences:
BADBIR is UK/Ireland–centric with deep longitudinal pharmacovigilance data; BSTOP specifically enriches this with biomarker and stratification researchOther registries may focus on different populations or disease outcomes without biomarker data linkage
Industry Recognition
Media Mentions:
Referenced extensively in dermatology research literature for biologic safety and treatment response studies
Endorsements:
Credibility Signals:
Recommended by UK health technology guidance to register patients receiving biologicsLarge multi‑centre real‑world database with thousands of participants
Government Regulation Status
Statutory Backing: Operates under UK research governance but not a statutory clinical register
Regulated By: Research ethics committees and institutional review boards
Legal Status: Approved clinical research register / cohort under UK research governance frameworks